Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (OptIMize)

9. november 2026 oppdatert av: Geron Corporation

A Randomized, Single-Blind, Multicenter Phase 4 Trial Evaluating Two Imetelstat Doses in Participants With Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS)

This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.

The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.

Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.

Taking part is voluntary. Participants may leave the study at any time.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Man or woman greater than or equal to (≥) 18 years of age
  • Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and biopsy within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
  • RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion Hgb should be ≤ 9.0 g/dL to count towards the 4 units total.
  • Relapsed/refractory to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

Exclusion Criteria:

  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
  • Prior treatment with imetelstat
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days of randomization
  • Has received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
  • Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or immunosuppressive therapy, within 4 weeks prior to randomization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Arm A: imetelstat 7.1 mg/kg

Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Eksperimentell: Arm B: imetelstat 3.55 mg/kg

Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study.

imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL
Tidsramme: Weeks 1-24

Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of Grade 3/4 thrombocytopenia by laboratory values
Tidsramme: Weeks 1-24

Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any

Weeks 1-24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of ≥ 12 weeks RBC TI
Tidsramme: Weeks 1-24

Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL
Tidsramme: Up to End of Study (approximately 3.5 years)

It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any.

Up to End of Study (approximately 3.5 years)
Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks
Tidsramme: Up to End of Study (approximately 3.5 years)

Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Duration of RBC TI Response
Tidsramme: Up to End of Study (approximately 3.5 years)

Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started.

Up to End of Study (approximately 3.5 years)
Time to RBC TI Response
Tidsramme: Up to End of Study (approximately 3.5 years)

It is defined as the interval from randomization to the first day of corresponsive RBC TI response

Up to End of Study (approximately 3.5 years)
Hgb peak and rise
Tidsramme: Up to End of Study (approximately 3.5 years)

Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level

Up to End of Study (approximately 3.5 years)
Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks
Tidsramme: Up to End of Study (approximately 3.5 years)

Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018
Tidsramme: Up to End of Study (approximately 3.5 years)

For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks.

For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry):

  • Major HI-E response per revised IWG 2018 is defined as 16-week RBC TI.
  • Minor HI-E response per revised IWG 2018 is defined as a reduction by at least 50% of RBC units over a 16-week period compared with the 16 weeks prior to trial entry.
Up to End of Study (approximately 3.5 years)
Rate of disease progression, including AML progression
Tidsramme: Up to End of Study (approximately 3.5 years)

Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria

Up to End of Study (approximately 3.5 years)
Rate of Grade 3/4 neutropenia by laboratory values
Tidsramme: Weeks 1-24

Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any

Weeks 1-24
Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Up to End of Study (approximately 3.5 years)

Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test [LFT] abnormalities)

Up to End of Study (approximately 3.5 years)
Time to Resolution of Lab Events
Tidsramme: Up to End of Study (approximately 3.5 years)

Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing.

Up to End of Study (approximately 3.5 years)
Assessment of Plasma concentrations of imetelstat
Tidsramme: Cycles 1-6 (28 day cycles)

Concentrations of imetelstat in Plasma

Cycles 1-6 (28 day cycles)
Assessment of Cmax
Tidsramme: Cycles 1-6 (28 day cycles)

Maximum Observed Plasma Concentration (Cmax)

Cycles 1-6 (28 day cycles)
Assessment of AUC
Tidsramme: Cycles 1-6 (28 day cycles)

Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration

Cycles 1-6 (28 day cycles)
Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks
Tidsramme: Cycles 1-6 (28 day cycles)
Cycles 1-6 (28 day cycles)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to acute myeloid leukemia (AML) progression among participants with documented AML progression
Tidsramme: Up to End of Study (approximately 3.5 years)
Up to End of Study (approximately 3.5 years)
Assessment of biomarkers
Tidsramme: Cycles 1-2 (28 day cycles)

At baseline and change from baseline

Cycles 1-2 (28 day cycles)
Assessment of Mutation status
Tidsramme: Up to End of Study (approximately 3.5 years)

At baseline and change from baseline including at the time of suspected progression

Up to End of Study (approximately 3.5 years)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Joseph E Eid, MD, Geron Corporation

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mars 2027

Primær fullføring (Antatt)

1. juli 2030

Studiet fullført (Antatt)

1. januar 2031

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • MDS4001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .